SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Coronavirus / COVID-19 Pandemic
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Investor2 who wrote (3062)5/20/2020 10:52:21 PM
From: Sam1 Recommendation

Recommended By
emertius

  Read Replies (1) of 22883
 
I don't understand that. On the following page, I find this:

What strategies for malaria treatment or chemoprevention can reduce the risk of life-threatening ventricular tachyarrhythmias following exposure to antimalarial medicines that induce QT interval prolongation?

In individuals with known heart disease, a family history of sudden unexplained death consistent with cardiac arrhythmia, or who are already taking medicines that can prolong the QT/QTc interval, antimalarial medicines that can induce QT/QTc interval prolongation should be used with caution. If possible, closer monitoring is advised when giving quinine, chloroquine, artesunate-amodiaquine or dihydroartemisinin-piperaquine to such individuals.

Plus, virtually everything I have read about this drug says that there are risks associated with blood pressure, heart attacks and blindness. It is a prescription drug because of these risks, its use needs to be monitored. It depends on dosage and how long it is used.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News